Stock Markets March 9, 2026

Macquarie Removes MakeMyTrip From Asia Marquee After 25% Share Drop

Broker cites steep rise in jet fuel prices and geopolitical pressures as near-term headwinds for international travel bookings

By Avery Klein MMYT
Macquarie Removes MakeMyTrip From Asia Marquee After 25% Share Drop
MMYT

Macquarie removed MakeMyTrip (NASDAQ:MMYT) from its Asia Marquee list after the stock fell 25% since being added on December 8, 2025. The broker highlighted an approximately 80% surge in jet fuel spot prices versus the December-quarter average and said geopolitical dynamics are pressuring international travel flows, which weigh on the company’s higher-exposure air ticketing segment even as the firm retains an Outperform rating.

Key Points

  • Macquarie removed MakeMyTrip from its Asia Marquee list after a 25% share price decline since December 8, 2025.
  • Macquarie cited an approximately 80% increase in jet fuel spot prices versus the December-quarter average and geopolitical headwinds affecting international travel.
  • MakeMyTrip’s international air segment is significant in booking terms - about 30% of air tickets booked and roughly 50% of air-ticket gross bookings - and the airline segment equals around 25% of overall gross bookings, while hotels carry higher margins and would benefit more from domestic travel.

Macquarie removed MakeMyTrip (NASDAQ:MMYT) from its Asia Marquee list on Monday, after the stock declined 25% since its inclusion on December 8, 2025. The broker pointed to a sharp rise in jet fuel costs and geopolitical tensions as material near-term challenges for the travel platform.

According to Macquarie, jet fuel spot prices have jumped roughly 80% compared with the average level seen in the December quarter. The broker emphasized the exposure of MakeMyTrip’s international business to routes linked to the Middle East - a region that accounts for approximately half of outbound travel from India. Within that outbound travel, Macquarie noted that roughly 40% is for leisure and about 15% is for business.

Macquarie’s note detailed the company’s air-ticketing mix: the international air segment represents about 30% of air tickets booked, and a higher share - roughly 50% - of air-ticketing gross bookings. When viewed across the platform, the airline segment constitutes approximately 25% of total gross bookings.

The broker also highlighted that the airline business contributes less on a revenue basis because of commoditized take-rates in air ticketing. By contrast, Macquarie said stronger domestic travel activity would primarily benefit MakeMyTrip’s hotels segment, which carries higher margins.

Despite removing the stock from its Asia Marquee list, Macquarie maintained its Outperform recommendation on MakeMyTrip. The firm warned, however, that it expects the stock to remain under pressure in the shorter term as a result of elevated jet fuel prices and ongoing geopolitical developments.


Context limitations: The broker’s comments and the company metrics cited above reflect the details provided in Macquarie’s note; no additional data or projections were supplied in that commentary.

Risks

  • Elevated jet fuel prices - an approximate 80% spike versus the December-quarter average - could continue to pressure airline-related revenues and booking dynamics, impacting travel and energy-sensitive sectors.
  • Geopolitical developments affecting outbound routes to and from the Middle East, which account for about half of India's outbound travel, may depress international leisure (around 40%) and business (around 15%) travel flows.
  • Compressed take-rates in air ticketing mean the airline segment contributes less to revenue, exposing MakeMyTrip’s earnings to shifts in air travel demand; hotel revenues are more margin-sensitive to domestic travel recovery.

More from Stock Markets

WuXi AppTec Shares Surge as Annual Profit More Than Doubles Mar 24, 2026 U.S. Stocks Showing Relative Resilience Amid Iran Conflict, but Risks Remain Mar 24, 2026 European New Car Registrations Tick Up in February as EV Momentum Continues Mar 24, 2026 Keymed Biosciences Set to Receive Up to $320 Million After Gilead Acquires Ouro Medicines Mar 24, 2026 Iran Fires Multiple Missile Waves at Israel as Negotiation Claims Are Disputed Mar 24, 2026